AR122090A1 - Moduladores de enpp1 y usos de los mismos - Google Patents
Moduladores de enpp1 y usos de los mismosInfo
- Publication number
- AR122090A1 AR122090A1 ARP210101325A ARP210101325A AR122090A1 AR 122090 A1 AR122090 A1 AR 122090A1 AR P210101325 A ARP210101325 A AR P210101325A AR P210101325 A ARP210101325 A AR P210101325A AR 122090 A1 AR122090 A1 AR 122090A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- halogen
- alkyl
- independently selected
- carbocycle
- Prior art date
Links
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 title abstract 3
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 title abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 19
- 150000002367 halogens Chemical class 0.000 abstract 19
- 125000001424 substituent group Chemical group 0.000 abstract 15
- 125000000623 heterocyclic group Chemical group 0.000 abstract 14
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 150000002431 hydrogen Chemical class 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Radar Systems Or Details Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Compuestos derivados de quinolina con actividad moduladora de ENPP1, composición farmacéutica que comprende a uno de éstos compuestos y el uso de los mismos para inhibir ENPP1 y activar la actividad de STING in vivo como así también para la activación de la respuesta inmunitaria contra un patógeno. Reivindicación 1: Un compuesto representado por la estructura de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde: X¹ se selecciona de N y C(R³); X² está ausente o se selecciona de O, S, C(R⁸)₂, N(R⁴) y C₃₋₆ carbociclo opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de R⁹; X³ se selecciona N y C(R³); Y se selecciona de N y C(H); R¹ se selecciona de: halógeno, -OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, y -CN; y C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, =O, =S, =N(R¹¹), -CN, C₃₋₆ carbociclo y heterociclo de 3 a 6 miembros; R² se selecciona de: hidrógeno, halógeno, -OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, y -CN; y C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, =O, =S, =N(R¹¹), -CN, C₃₋₆ carbociclo y heterociclo de 3 a 6 miembros; R³ se selecciona de: hidrógeno, halógeno, -OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, y -CN; y C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, =O, =S, =N(R¹¹), -CN, C₃₋₆ carbociclo y heterociclo de 3 a 6 miembros; R³ se selecciona de: hidrógeno, halógeno, -OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, y -CN; y C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, OR¹¹, -SR¹¹, -N(R¹¹)₂, -C(O)R¹¹, -C(O)N(R¹¹)₂, -N(R¹¹)C(O)R¹¹, -C(O)OR¹¹, -OC(O)R¹¹, -S(O)R¹¹, -S(O)₂R¹¹, -S(O)₂N(R¹¹)₂, -N(R¹¹)S(O)₂R¹¹, -S(O)(NR¹¹)R¹¹, -S(NR¹¹)₂R¹¹, -NO₂, =O, =S, =N(R¹¹), -CN, C₃₋₆ carbociclo y heterociclo de 3 a 6 miembros; L está ausente o se selecciona de metileno opcionalmente sustituidos con uno o más sustituyentes seleccionados de halógeno, -OR²¹, -SR²¹, -N(R²¹)₂, -C(O)R²¹, -C(O)N(R²¹)₂, -N(R²¹)C(O)R²¹, -C(O)OR²¹, -OC(O)R²¹, -S(O)R²¹, -S(O)₂R²¹, -NO₂, y -CN; el anillo A se selecciona de un C₃₋₁₀ carbociclo opcionalmente sustituido y heterociclo de 3 a 10 miembros opcionalmente sustituido, en donde los sustituyentes en el anillo A se seleccionan independientemente en cada aparición de: halógeno, -OR³¹, -SR³¹, -N(R³¹)₂, -C(O)R³¹, -C(O)N(R³¹)₂, -N(R³¹)C(O)R³¹, -C(O)OR³¹, -OC(O)R³¹, -S(O)R³¹, -S(O)₂R³¹, -NO₂, =O, -CN, y C₁₋₅ haloalquilo; y C₁₋₅ alquilo C₂₋₅ alquenilo, C₂₋₅ alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR³¹, -SR³¹, -N(R³¹)₂, -C(O)R³¹, -C(O)N(R³¹)₂, -N(R³¹)C(O)R³¹, -C(O)OR³¹, -OC(O)R³¹, -S(O)R³¹, -S(O)₂R³¹, -NO₂, =O, y -CN; R⁴ se selecciona de hidrógeno, C₁₋₅ alquilo y C₃₋₆ carbociclo, en donde C₁₋₅ alquilo y C₃₋₆ carbociclo están sustituidos opcionalmente con uno o más sustituyentes seleccionados independientemente de R⁹; R⁵, R⁶ y R⁷ se seleccionan cada uno independientemente de hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₁₂ carbociclo opcionalmente sustituido y heterociclo de 3 a 12 miembros opcionalmente sustituido; o R⁵ y R⁶ se unen para formar un heterociclo opcionalmente sustituido de 5 a 8 miembros, y R⁷ se selecciona de hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₁₂ carbociclo opcionalmente sustituido y heterociclo de 3 a 12 miembros opcionalmente sustituido; o R⁶ y R⁷ se unen para formar un heterociclo de 5 a 8 miembros opcionalmente sustituido, y R⁵ se selecciona de hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₁₂ carbociclo opcionalmente sustituido y heterociclo de 3 a 12 miembros opcionalmente sustituido; en donde los sustituyentes en R⁵, R⁶ y R⁷ o anillos formados a partir de estos se seleccionan independientemente en cada aparición de: halógeno, -OR⁴¹, -SR⁴¹, -N(R⁴¹)₂, -C(O)R⁴¹,-C(O)N(R⁴¹)₂, -N(R⁴¹)C(O)R⁴¹, -N(R⁴¹)C(O)OR⁴¹, -C(O)OR⁴¹, -OC(O)R⁴¹, -S(O)R⁴¹, -S(O)₂R⁴¹, -S(O)₂N(R₄₁)₂, -N(R⁴¹)S(O)₂R⁴¹, -S(O)(NR⁴¹)R⁴¹, -S(NR⁴¹)₂R⁴¹, -NO₂, =O, =S, =N(R⁴¹), y -CN; y C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR⁴¹, -SR⁴¹, -N(R⁴¹)₂, -C(O)R⁴¹, -C(O)N(R⁴¹)₂, -N(R⁴¹)C(O)R⁴¹, -N(R⁴¹)C(O)OR⁴¹, -C(O)OR⁴¹, -OC(O)R⁴¹, -S(O)R⁴¹, -S(O)₂R⁴¹, -S(O)₂N(R⁴¹)₂, -N(R⁴¹)S(O)₂R⁴¹, -S(O)(NR⁴¹)R⁴¹, -S(NR⁴¹)₂R⁴¹, -NO₂, =O, =S, =N(R⁴¹), -CN, C₃₋₁₂ carbociclo y heterociclo de 3 a 12 miembros; C₃₋₁₂ carbociclo y heterociclo de 3 a 12 miembros cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR⁴¹, -SR⁴¹, -N(R⁴¹)₂, -C(O)R⁴¹, -C(O)N(R⁴¹)₂, -N(R⁴¹)C(O)R⁴¹, -N(R⁴¹)C(O)OR⁴¹, -C(O)OR⁴¹, -OC(O)R⁴¹, -S(O)R⁴¹, -S(O)₂R⁴¹, -S(O)₂N(R⁴¹)₂, -N(R⁴¹)S(O)₂R⁴¹, -S(O)(NR⁴¹)R⁴¹, -S(NR⁴¹)₂R⁴¹, -NO₂, =O, =S, =N(R⁴¹), -CN, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, C₃₋₁₂ carbociclo y heterociclo de 3 a 12 miembros; cada R⁸ se selecciona independientemente de: hidrógeno, halógeno, -OR⁵¹, -SR⁵¹, -N(R⁵¹)₂, -NO₂ y -CN; y C₁₋₅ alquilo opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR⁵¹, -SR⁵¹, -N(R⁵¹)₂, -NO₂ y -CN; cada R⁹ se selecciona independientemente de: halógeno, -OR⁶¹, -SR⁶¹, -N(R⁶¹)₂, -NO₂ y -CN; y C₁₋₅ alquilo opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OR⁶¹, -SR⁶¹, -N(R⁶¹)₂, -NO₂ y -CN; cada R¹¹, R²¹, R³¹, R⁴¹, R⁵¹ y R⁶¹ se selecciona independientemente de: hidrógeno; y C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, C₃₋₈ carbociclo y 3 a 8 miembros heterociclo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, -OH, -CN, -NO₂, -NH₂, =O, =S, C₁₋₅ alquilo, -C₁₋₅ haloalquilo y -O-C₁₋₅ alquilo; y z se selecciona de 0 - 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063024937P | 2020-05-14 | 2020-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122090A1 true AR122090A1 (es) | 2022-08-10 |
Family
ID=76250495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101325A AR122090A1 (es) | 2020-05-14 | 2021-05-13 | Moduladores de enpp1 y usos de los mismos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230183188A1 (es) |
EP (1) | EP4149927A1 (es) |
JP (1) | JP2023526050A (es) |
KR (1) | KR20230012535A (es) |
CN (1) | CN116348451A (es) |
AR (1) | AR122090A1 (es) |
AU (1) | AU2021273001A1 (es) |
BR (1) | BR112022023112A2 (es) |
CA (1) | CA3178372A1 (es) |
IL (1) | IL298169A (es) |
MX (1) | MX2022014126A (es) |
TW (1) | TW202208336A (es) |
WO (1) | WO2021231726A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023086638A1 (en) * | 2021-11-15 | 2023-05-19 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
WO2023220402A1 (en) * | 2022-05-13 | 2023-11-16 | Gossamer Bio Services, Inc. | Enpp1 modulators and products and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
KR20040068613A (ko) | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
KR20190126283A (ko) * | 2016-12-22 | 2019-11-11 | 마브파마, 인크. | 포스포디에스테라아제 저해제 및 미생물 치료 방법 |
AU2020353005A1 (en) * | 2019-09-23 | 2022-04-14 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
-
2021
- 2021-05-13 EP EP21729757.1A patent/EP4149927A1/en active Pending
- 2021-05-13 BR BR112022023112A patent/BR112022023112A2/pt not_active Application Discontinuation
- 2021-05-13 MX MX2022014126A patent/MX2022014126A/es unknown
- 2021-05-13 CN CN202180060383.XA patent/CN116348451A/zh active Pending
- 2021-05-13 JP JP2022568810A patent/JP2023526050A/ja active Pending
- 2021-05-13 KR KR1020227043581A patent/KR20230012535A/ko unknown
- 2021-05-13 IL IL298169A patent/IL298169A/en unknown
- 2021-05-13 AU AU2021273001A patent/AU2021273001A1/en active Pending
- 2021-05-13 TW TW110117372A patent/TW202208336A/zh unknown
- 2021-05-13 CA CA3178372A patent/CA3178372A1/en active Pending
- 2021-05-13 WO PCT/US2021/032249 patent/WO2021231726A1/en active Application Filing
- 2021-05-13 AR ARP210101325A patent/AR122090A1/es unknown
-
2022
- 2022-11-16 US US17/988,575 patent/US20230183188A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022023112A2 (pt) | 2023-01-17 |
CN116348451A (zh) | 2023-06-27 |
WO2021231726A1 (en) | 2021-11-18 |
US20230183188A1 (en) | 2023-06-15 |
EP4149927A1 (en) | 2023-03-22 |
MX2022014126A (es) | 2023-04-10 |
KR20230012535A (ko) | 2023-01-26 |
TW202208336A (zh) | 2022-03-01 |
JP2023526050A (ja) | 2023-06-20 |
IL298169A (en) | 2023-01-01 |
CA3178372A1 (en) | 2021-11-18 |
AU2021273001A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122090A1 (es) | Moduladores de enpp1 y usos de los mismos | |
AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
AR119770A1 (es) | Proceso de elaboración de moduladores de cftr | |
AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
AR088565A1 (es) | Inhibidor de cetp de oxazolidinona biciclico fusionado | |
AR108709A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR117616A1 (es) | Compuestos anti-vih | |
AR099890A1 (es) | Inhibidores de histona demetilasas | |
AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
AR120773A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz | |
AR111248A1 (es) | Derivados de ciclopropilmetilamida activos como pesticida | |
AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
AR120377A1 (es) | Derivados heteroaromáticos de sulfiliminas o sulfoximinas con actividad fungicida | |
AR104533A1 (es) | Derivados de ácido ciclopropano carboxílico y sus usos como inhibidores de leucotrieno c₄ sintasa | |
AR096827A1 (es) | Uso de piridoncarboxamidas seleccionadas o sus sales como ingredientes activos contra estrés abiótico en plantas | |
AR111282A1 (es) | Inhibidores de cdpk1 ii, composiciones y métodos relacionados con los mismos | |
AR105060A1 (es) | Concentrado emulsionable que comprende un herbicida de ácido fenoxi-alcanoico |